Secretory Leukocyte Protease Inhibitor (SLPI): Emerging Roles in CNS Trauma and Repair

Neuroscientist

Volumn 21, Issue 6, 2015, Pages 630-636

  Hannila, Sari S ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

brain; inflammation; ischemia; regeneration; SLPI; spinal cord injury

Indexed keywords

NEUROPROTECTIVE AGENT; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR;

ANTIMICROBIAL ACTIVITY; BRAIN INJURY; BRAIN ISCHEMIA; CELLULAR DISTRIBUTION; CENTRAL NERVOUS SYSTEM; CONTROLLED CLINICAL TRIAL (TOPIC); DOWN REGULATION; HUMAN; MOTOR PERFORMANCE; MULTIPLE SCLEROSIS; NERVE CELL PLASTICITY; NERVE FIBER GROWTH; NERVE FIBER REGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REGENERATION; REVIEW; SPINAL CORD INJURY; SPINAL GANGLION; UPREGULATION; WOUND HEALING; ANIMAL; CONVALESCENCE; DEGENERATIVE DISEASE; ENZYMOLOGY; METABOLISM; NERVE REGENERATION; PHYSIOLOGY;

ANIMALS; BRAIN ISCHEMIA; HUMANS; NERVE REGENERATION; NEURODEGENERATIVE DISEASES; RECOVERY OF FUNCTION; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR; SPINAL CORD INJURIES;

EID: 84946111471     PISSN: 10738584     EISSN: 10894098     Source Type: Journal    
DOI: 10.1177/1073858414546000     Document Type: Review

References (28)

1. Abe T, Kobayashi N, Yoshimura K, Trapnell BC, Kim H, Hubbard RC, and others. 1991. Expression of the secretory leukoprotease inhibitor gene in epithelial cells. J Clin Invest 87: 2207-15.
2. Ashcroft GS, Lei K, Jin W, Longenecker G, Kulkarni AB, Greenwell-Wild T, and others. 2000. Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing. Nat Med 6: 1147-53.
3. Cooper MD, Roberts MH, Barauskas OL, Jarvis GA,. 2012. Secretory leukocyte protease inhibitor binds to Neisseria gonorrhoeae outer membrane opacity protein and is bactericidal. Am J Reprod Immunol 68: 116-27.
4. Doumas S, Kolokotronis A, Stefanopoulos P,. 2005. Anti-inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor. Infect Immun 73: 1271-4.
5. Drannik AG, Henrick BM, Rosenthal KL,. 2011. War and peace between WAP and HIV: role of SLPI, trappin-2, elafin and ps20 in susceptibility to HIV infection. Biochem Soc Trans 39: 1427-32.
6. Eisenberg SP, Hale KK, Heimdal P, Thompson RC,. 1990. Location of the protease-inhibitory region of secretory leukocyte protease inhibitor. J Biol Chem 265: 7976-81.
7. Ghasemlou N, Bouhy D, Yang J, López-Vales R, Haber M, Thuraisingam T, and others. 2010. Beneficial effects of secretory leukocyte protease inhibitor after spinal cord injury. Brain 133: 126-38.
8. Gomez SA, Argüelles CL, Guerrieri D, Tateosian NL, Amiano NO, Slimovich R, and others. 2009. Secretory leukocyte protease inhibitor: a secreted pattern recognition receptor for mycobacteria. Am J Respir Crit Care Med 179: 247-53.
9. Grütter MG, Fendrich G, Huber R, Bode W,. 1988. The 2.5 A X-ray crystal structure of the acid-stable proteinase inhibitor from human mucous secretions analysed in its complex with bovine alpha-chymotrypsin. EMBO J 7: 345-51.
10. Hannila SS, Siddiq MM, Carmel JB, Hou J, Chaudhry N, Bradley PMJ, and others. 2013. Secretory leukocyte protease inhibitor reverses inhibition by CNS myelin, promotes regeneration in the optic nerve, and suppresses expression of the TGFβ signaling protein Smad2. J Neurosci 33: 5138-51.
11. Henriksen PA, Hitt M, Xing Z, Wang J, Haslett C, Riemersma RA, and others. 2004. Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-kappa B-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli. J Immunol 172: 4535-44.
12. Hiemstra PS, Maassen RJ, Stolk J, Heinzel-Wieland R, Steffens GJ, Dijkman JH,. 1996. Antibacterial activity of antileukoprotease. Infect Immun 64: 4520-4.
13. Iecka J, Stelmasiak Z,. 2002. Increased serum levels of endogenous protectant secretory leukocyte protease inhibitor in acute ischemic stroke patients. Cerebrovasc Dis 13: 38-42.
14. Jin FY, Nathan C, Radzioch D, Ding A,. 1997. Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell 88: 417-26.
15. Kikuchi T, Abe T, Hoshi S, Matsubara N, Tominaga Y, Satoh K, and others. 1998. Structure of the murine secretory leukoprotease inhibitor (Slpi) gene and chromosomal localization of the human and murine SLPI genes. Am J Respir Cell Mol Biol. 19: 875-80.
16. Lentsch AB, Yoshidome H, Warner RL, Ward PA, Edwards MJ,. 1999. Secretory leukocyte protease inhibitor in mice regulates local and remote organ inflammatory injury induced by hepatic ischemia/reperfusion. Gastroenterology 117: 953-61.
17. Lilo E, Wald-Altman S, Solmesky LJ, Ben Yaakov K, Gershoni-Emek N, Bulvik S, and others. 2013. Characterization of human sporadic ALS biomarkers in the familial ALS transgenic mSOD1(G93A) mouse model. Hum Mol Genet 22: 4720-5.
18. Ma G, Greenwell-Wild T, Lei K, Jin W, Swisher J, Hardegen N, and others. 2004. Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J Exp Med 200: 1337-46.
19. McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM,. 1995. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest 96: 456-64.
20. Miller KW, Evans RJ, Eisenberg SP, Thompson RC,. 1989. Secretory leukocyte protease inhibitor binding to mRNA and DNA as a possible cause of toxicity to Escherichia coli. J Bacteriol 171: 2166-72.
21. Moriyama A, Shimoya K, Ogata I, Kimura T, Nakamura T, Wada H, and others. 1999. Secretory leukocyte protease inhibitor (SLPI) concentrations in cervical mucus of women with normal menstrual cycle. Mol Hum Reprod 5: 656-61.
22. Mueller AM, Pedré X, Stempfl T, Kleiter I, Couillard-Despres S, Aigner L, and others. 2008. Novel role for SLPI in MOG-induced EAE revealed by spinal cord expression analysis. J Neuroinflammation 5: 20.
23. Py B, Basmaciogullari S, Bouchet J, Zarka M, Moura IC, Benhamou M, and others. 2009. The phospholipid scramblases 1 and 4 are cellular receptors for the secretory leukocyte protease inhibitor and interact with CD4 at the plasma membrane. PLoS One 4: e5006.
24. Schneeberger S, Hautz T, Wahl SM, Brandacher G, Sucher R, Steinmassl O, and others. 2008. The effect of secretory leukocyte protease inhibitor (SLPI) on ischemia/reperfusion injury in cardiac transplantation. Am J Transplant 8: 773-82.
25. Stegmüller J, Huynh MA, Yuan Z, Konishi Y, Bonni A,. 2008. TGFbeta-Smad2 signaling regulates the Cdh1-APC/SnoN pathway of axonal morphogenesis. J Neurosci 28: 1961-9.
26. Taggart CC, Cryan SA, Weldon S, Gibbons A, Greene CM, Kelly E, and others. 2005. Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding. J Exp Med 202: 1659-68.
27. Thompson RC, Ohlsson K,. 1986. Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc Natl Acad Sci U S A 83: 6692-6.
28. Wang X, Li X, Xu L, Zhan Y, Yaish-Ohad S, Erhardt JA, and others. 2003. Up-regulation of secretory leukocyte protease inhibitor (SLPI) in the brain after ischemic stroke: adenoviral expression of SLPI protects brain from ischemic injury. Mol Pharmacol 64: 833-40.